PC
ABBV icon

Promethos Capital’s AbbVie ABBV Stock Holding History

Promethos Capital’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-30,278
Closed -$5.98M – 83
2024
Q3 		$5.98M Hold
30,278
– – 2.13% 17
2024
Q2 		$5.19M Buy
30,278
+16,510
+120% +$2.73M 1.97% 19
2024
Q1 		$2.51M Hold
13,768
– – 1.47% 18
2023
Q4 		$2.13M Buy
+13,768
New +$2.01M 1.55% 15

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Koshinski Asset Management
Koshinski Asset Management Decatur, Illinois $1.6B AUM 20.7% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Promethos Capital's ABBV Position: Q4 2024 in Review

Promethos Capital sold out of AbbVie (ABBV) in Q4 2024, closing a stake of 30,278 shares — an estimated $5.98M sold.

Promethos Capital first reported a position in ABBV in Q4 2023 and held it in 4 quarters. The position peaked at $5.98M in Q3 2024. 3,744 funds tracked by Wall St. Rank hold ABBV as of Q4 2024.

  • Promethos Capital reported no remaining AbbVie position as of Q4 2024 after selling out during the quarter.
  • Promethos Capital sold 30,278 AbbVie shares in Q4 2024, an estimated $5.98M.
  • Promethos Capital first reported a position in AbbVie in Q4 2023 and held it in 4 quarters.
  • Promethos Capital's AbbVie position peaked at $5.98M in Q3 2024.
  • 3,744 funds tracked by Wall St. Rank held AbbVie as of Q4 2024.

Based on Promethos Capital's 13F filing for Q4 2024, filed 13 Feb 2025.